326599-34-2

Upstream product

• 326599-32-0 Methyl (1R,3R,5S)-3-t-butyldiphenylsilyloxy-5-hydroxy-cyclohexane-carboxylate 
• 326598-94-1 (1S,3S,5R)-3-acetoxy-5-hydroxy-1-(methoxycarbonyl)cyclohexane 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 326599-33-1 methyl (1S,3R,5S)-3-(tert-butyldiphenylsilyloxy)-5-tosyloxycyclohexanecarboxylate 

Downstream Products

• 326599-37-5 (2S,3aR,4aR)-2-(tert-butyldiphenylsilyloxy)bicyclo[3.1.0]hexane-3a-carbaldehyde 
• 386766-87-6 C₂₃H₂₇⁽²⁾HO₂Si 
• 386766-81-0 (1S,3R)-3-(tert-Butyl-diphenyl-silanyloxy)-5-[2-[(1R,3aR,7aR)-1-((R)-5-hydroxy-1,5-dimethyl-hex-3-ynyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-cyclohexanol 
• 326599-36-4 [(1R,3S,5R)-3-(tert-Butyl-diphenyl-silanyloxy)-bicyclo[3.1.0]hex-1-yl]-methanol 

Relevant academic research and scientific papers

A practical synthesis of 14-epi-19-nor-1α,25-dihydroxyvitamin D3 analogues and their A-ring epimers

A practical synthesis of (2S,3aS,4aS)-2-tert-butyldimethylsilyloxybicyclo[3.1.0]hexane-3a-carbaldehyde (14a) and diastereoisomers, starting from all-cis methyl 3,5-dihydroxy-1cyclohexanecarboxylate (24) is described. Coupling with appropriate cis-hydrindanes produces the title compounds. TX 522, a member of this series, is currently in phase II clinical studies for the treatment of psoriasis. The key step involves the coupling of 14 and 16 with the respective cis-hydrindanes 9 and 7.